WASHINGTON — Underneath stress of tariffs and worth controls from the Trump administration, AstraZeneca introduced Monday that it might make investments $50 billion by 2030.
AstraZeneca’s CEO, Pascal Soriot, flanked by Trump administration officers and Virginia Gov. Glenn Youngkin, added that, as a part of the funding, the corporate would construct a multi-billion-dollar manufacturing website in Virginia.
That facility, which can produce medicine for weight administration, together with GLP-1s, would be the “cornerstone” of the brand new investments within the U.S., Soriot mentioned.
This text is unique to STAT+ subscribers
Unlock this text — plus day by day protection and evaluation of the pharma business — by subscribing to STAT+.
Have already got an account? Log in
To learn the remainder of this story subscribe to STAT+.
